Gefapixant
Idiopathic Pulmonary Fibrosis
Clinical trials
2
Developer
Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Overview
Gefapixant is an agent tracked by PF-Atlas in the context of idiopathic pulmonary fibrosis. It appears in 2 tracked IPF clinical trials.
Gefapixant clinical trials
Explore related
Medical disclaimer. This page summarizes research about Gefapixant for information only. It is not medical advice. Verify approval status and evidence with the FDA and a pulmonologist.